Key Documents

View All Documentation

D104981

Dibenzosuberone

Name: Dibenzosuberone
Brand: ALDRICH

98%

Synonym(s):

5-Dibenzosuberone, 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one, Dibenzocycloheptadienone

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₂O

CAS Number:

1210-35-1

Molecular Weight:

208.26

EC Number:

214-912-3

UNSPSC Code:

12352100

PubChem Substance ID:

24893335

Beilstein/REAXYS Number:

1454355

MDL number:

MFCD00003587

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

assay

98%

refractive index

n20/D 1.6332 (lit.)

bp

148 °C/0.3 mmHg (lit.)

mp

32-34 °C (lit.)

density

1.156 g/mL at 25 °C (lit.)

SMILES string

O=C1c2ccccc2CCc3ccccc13

InChI

1S/C15H12O/c16-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8H,9-10H2

InChI key

BMVWCPGVLSILMU-UHFFFAOYSA-N

Description

Still not finding the right product?

Explore all of our products under Dibenzosuberone

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The control of impurities in amitriptyline hydrochloride using a reversed-phase hybrid stationary phase.

S P Dixon et al.

Pharmeuropa scientific notes, 2005(1), 15-20 (2007-08-11)

An isocratic reversed-phase liquid chromatographic method is described using a hybrid column for the control of synthetic impurities potentially found in amitriptyline hydrochloride. The method has been validated and is capable of controlling impurities to 0.1 per cent.

Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.

Solveigh C Koeberle et al.

Journal of medicinal chemistry, 55(12), 5868-5877 (2012-06-09)

Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, improving physicochemical properties as well as potency.

Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.

Stefan Fischer et al.

Journal of medicinal chemistry, 56(1), 241-253 (2012-12-29)

p38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases. Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market. This might be attributed to the fact that there is no inhibitor

View All Related Papers